* Transmedics Group Inc TMDX.OQ TMDX.O is expected
to show a
rise in quarterly revenue when it reports results on July 31
for the period ending June 30 2024
* The Andover Massachusetts-based company is expected to
report a
88.6% increase in revenue to $98.969 million from $52.47 million
a year ago, according to the mean estimate from 8 analysts,
based on LSEG data.
* LSEG's mean analyst estimate for Transmedics Group Inc is
for
earnings of 21 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Transmedics
Group
Inc is $151.00, above its last closing price of $139.00.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2024 -0.04 -0.04 0.35 Beat 975
Dec. 31 2024 -0.03 -0.06 0.12 Beat 293.5
Sep. 30 2023 -0.16 -0.16 -0.78 Missed -382.5
Jun. 30 2023 -0.11 -0.13 -0.03 Beat 76.9
Mar. -0.21 -0.25 -0.08 Beat 67.5
31 2023
Dec. 31 2022 -0.30 -0.30 -0.21 Beat 30
Sep. 30 2022 -0.43 -0.41 -0.25 Beat 39.3
Jun. 30 2022 -0.35 -0.35 -0.41 Missed -17.8
This summary was machine generated July 29 at 22:52 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)